5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Panacea Biotec Ltd.

•
panaceabiotec.comBSE: 531349NSE: PANACEABIO
Market Cap₹ 2,438 Cr.
Current Price
High / Low₹ 647 / 292
Stock P/E0.0
Book Value₹ 47
Price to Book8.60
Dividend Yield0.00 %
ROCE-2.1 %
ROE-4.7 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2019 • Vaccines: 100.0% • Research & Development: 0.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 120.7% YoY, showing strong momentum
  • Operating margins have improved to -2.2% from -25.4%
  • Institutional investors have been accumulating - FII+DII up 2.3pp

CONS

  • Company is loss-making at the operating / net level
  • Receivables are growing faster than sales - a possible quality concern
  • Company has a low return on equity of -9.1% over last 3 years
  • Company has a low return on capital employed of -3.1%
  • Interest coverage is weak at -0.7x - earnings barely cover interest
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.26x)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.PANACEABIO398.050.002438.090.002.20-44.44199.5719.72-0.472.84
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
899595805777108681129199111135
8385899067709386115105101111139
Operating Profit7107-9-10715-19-3-14-10-4
OPM %7.62%10.53%6.97%-11.50%-18.44%8.79%14.19%-27.35%-2.69%-15.09%-1.39%0.27%-3.01%
32316433654466
Interest3433344566767
Depreciation5555555555544
Profit before Tax131-1-15110-22-9-21-9-52
Tax %0.00%0.00%59.81%-1.48%8.01%0.77%0.00%43.76%24.21%25.27%22.28%96.10%30.50%
Net Profit130-1-14110-12-7-16-7-01
0.210.520.07-0.22-2.250.211.58-2.02-1.09-2.55-1.20-0.030.23

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
647530574444490344236257360310436
534461493591480343308320345317455
Operating Profit1136981-147100-73-6314-7-19
OPM %17.39%13.11%14.18%-33.01%2.05%0.14%-30.86%-24.36%3.94%-2.24%-4.32%
75161834229211334251719
Interest1151041031051478710141526
Depreciation7166575427272624212018
Profit before Tax1-84-6137-136-13-94-634-26-33
Tax %37.86%13.54%-17.38%28.53%-12.58%-12.15%-0.00%-39.51%15.60%41.56%33.99%
Net Profit1-73-7227-153-14-94-884-15-22
EPS0.000.000.000.000.00-2.35-15.28-14.290.58-2.49—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
-8%
5 Years:
-9%
3 Years:
10%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
14%
5 Years:
6%
3 Years:
45%
1 Year:
-7%

RETURN ON EQUITY

10 Years:
-11%
5 Years:
-10%
3 Years:
-9%
Last Year:
-5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

No bonus data found

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
6666666666
518450382412855502409320323308
9971,029974689737387108135238
Trade Payables17422724278136124145129116165
283209218407238256287333345164
Total Liabilities1,9781,9201,8221,5931,307962933895925881
988942891496447398416385357348
Capital Work in Progress96534131167187
3953453453300000
137141149439987129116108152
000000001121
Cash & Bank97128618943431262
4414794201,041694374344334366210
Total Assets1,9781,9201,8221,5931,307962933895925881

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
7798173107-7539-52-10334
Cash from Investing23-18-3-8-19-37402-47-61
Cash from Financing-129-91-164-98109-71091390
-8-5608-6-31-133

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
73.4672.8772.4972.4872.4872.4872.4872.4872.48
0.260.370.381.160.791.061.361.602.31
1.071.161.161.491.521.801.851.962.25
Government0.000.000.000.000.000.000.000.000.00
25.2025.6025.9724.8725.2224.6624.3123.9622.96

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Copy of Newspaper Publication

2026-09-08 - Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication - Post dispatch of AGM Notice

2026-09-07
General Updates

2026-09-07 - Panacea Biotec Limited has informed the Exchange about General Updates - Book closure for the purpose of AGM

2026-09-07
General Updates

2026-09-07 - Panacea Biotec Limited has informed the Exchange about General Updates - Confirmation on letter being sent to the concerned shareholders providing the weblink for accessing the Annual Report for financial year 2025-26 and the Notice of the ensuing AGM, to be held on September 29, 2026, through Video Conferencing / Other Audio-Visual Means.

2026-09-07
Shareholders meeting

2026-09-07 - Panacea Biotec Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026

2026-09-07
Updates

2026-09-07 - Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during August 2026'.

2026-08-18
Copy of Newspaper Publication

2026-08-18 - Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-14
Copy of Newspaper Publication

2026-08-14 - Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
Outcome of Board Meeting

2026-08-13 - Panacea Biotec Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-08-12
Copy of Newspaper Publication

2026-08-12 - Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication

News

Recent coverage and analyst commentary for PANACEABIO

Loading news…

🤖

AI Stock Analyst

Panacea Biotec Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login